Analyst Ratings for Washington Federal

Analysts have provided the following ratings for Washington Federal (NASDAQ:WAFD) within the last quarter: Bullish Somewhat Bullish Indifferent…

Analysts have provided the following ratings for Washington Federal (NASDAQ:WAFD) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 2 1 0 0
Last 30D 1 1 1 0 0
1M Ago 0 1 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

These 4 analysts have an average price target of $35.75 versus the current price of Washington Federal at $28.5, implying upside.

Below is a summary of how these 4 analysts rated Washington Federal over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 10.06% from the previous average price target of $39.75.

Stay up to date on Washington Federal analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Is This A Miracle Drug For ‘Sticky Cholesterol’? Analysts Applaud Safety, Efficacy Of Silence Therapeutics’ Heart Disease Candidate

Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a) (Lp(a), levels at or over 150 nmol/L and stable atherosclerotic 

SLN

Read More

Watching Microvast Holdings; J Capital Issues Short Report Headlined ‘J Capital Is Short Microvast Empty Facilities and Hiding the Loss of a $200M Grant: Another China Hustle’

https://www.jcapitalresearch.com/mvst.htmlJ Capital Research ("J Cap") is a stock-research and media company. J Cap has analyzed the U.S.-listed company Microvast Holdings. ("MVST") and is hereby publishing the outcome

MVST